Effects of single intraperitoneal injections of an extract of Ginkgo biloba (EGb 761) and its terpene trilactone constituents on barbital-induced narcosis in the mouse

General Pharmacology

Volumn 33, Issue 3, 1999, Pages 249-256

  Brochet, Denis ^a   Chermat, Raymond ^a   DeFeudis, Francis V ^b   Drieu, Katy ^c  

^a Psypharm SA   (France)

^b Institute for BioScience   (United States)

^c Institut Henri Beaufour   (France)

Author keywords

Antidepressant; Barbital; Bilobalide; GABA receptor; Ginkgo biloba; Ginkgolide B

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANTIDEPRESSANT AGENT; BARBITAL; BILOBALIDE; CAFFEINE; CHLORIDE CHANNEL; GINKGO BILOBA EXTRACT; GINKGOLIDE A; GINKGOLIDE B; TERPENE DERIVATIVE;

ALERTNESS; ANESTHESIA; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RIGHTING REFLEX;

ANALYSIS OF VARIANCE; ANESTHESIA; ANIMALS; BARBITAL; CAFFEINE; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; GINKGO BILOBA; GINKGOLIDES; INJECTIONS, INTRAPERITONEAL; LACTONES; MALE; MICE; MICE, INBRED STRAINS; NEUROPROTECTIVE AGENTS; PLANT EXTRACTS; SLEEP; TIME FACTORS;

EID: 0032764860     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(99)00018-X     Document Type: Article

References (46)

1. Allain H., Raoul P., Lieury A., LeCoz F., Gandon J.M., d'Arbigny P. Effect of two doses of Ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects. Clin Ther. 15:1993;549-558.
2. Allard M. Traitement des troubles du vieillissement et extrait de Ginkgo biloba. De la pharmacologie à la clinique. Press Méd. 15:1986;1540-1545.
3. Amri, H., Drieu, K., Papadopoulos, V., 1997. Regulation of peripheral benzodiazepine receptor, glucocorticoid synthesis and neuroprotection by the Ginkgo biloba extract (EGb 761) and isolated ginkgolide B. In: Papadopoulos, V., Drieu, K., Christen, Y. (Eds.), Advances in Ginkgo biloba extract research, Vol. 6. Adaptive effects of Ginkgo biloba extract (EGb 761). Elsevier, Paris, pp. 117-127.
4. Amri H., Ogwuegbu S.O., Boujrad N., Drieu K., Papadopoulos V. In vivo regulation of the peripheral-type benzodiazepine receptor and glucocorticoid synthesis by the Ginkgo biloba extract EGb 761 and isolated ginkgolides. Endocrinology. 137:1996;5707-5718.
5. Auguet M., Delaflotte S., Hellegouarch A., Clostre F. Bases pharmacologiques de l'impact vasculaire de l'extrait de Ginkgo biloba. Presse Méd. 15:1986;1524-1528.
6. BGA-Kommission E., 1994. Monographie: Trockenextrakt (35-67:1) aus Ginkgo-biloba-Blättern, extrahiert mit Aceton-Wasser. Bundesanzeiger (Banz.), No. 133, 19 July 1994, p. 7361.
7. Boissier J.R., Simon P. Factors influencing the interaction between hypnotics and a variety of other drugs. Tedeschi D.H., Tedeschi R.E. Importance of fundamental principles in drug evaluation. 1968;307-324 Raven Press, New York.
8. Braquet P., Paubert-Braquet M., Bourgain R.H., Bussolino F., Hosford D. PAF/cytokine auto-generated feedback networks in microvascular immune injury. consequences in shock, ischemia and graft injection J Lipid Mediators. 1:1989;75-112.
9. Chandrasekaran, K., Liu, L.I., Hatanpää, K., Drieu, K., Rapoport, S.I., 1998. Stimulation of mitochondrial gene expression by bilobalide, a constituent of Ginkgo biloba extract (EGb 761). In: Packer, L., Christen, Y. (Eds.), Advances in Ginkgo biloba extract research, Vol. 7. Ginkgo biloba extract (EGb 761): lessons from cell biology. Elsevier, Paris, pp. 121-128.
10. Chatterjee, S.S., Gabard, B.L., Jaggy, H.E.W., 1986. Pharmaceutical compositions containing bilobalid for the treatment of neuropathies. U.S. Patent No. 4,571,407.
11. A receptors. Ann NY Acad Sci. 585:1990;231-240.
12. DeFeudis F.V. Ginkgo biloba extract (EGb 761): pharmacological activities and clinical applications. 1991;Elsevier, Paris.
13. Drieu K. Préparation et définition de l'extrait de Ginkgo biloba. Press Méd. 15:1986;1455-1457.
14. 14C in tolerant and non-tolerant rats. Biochem Pharmacol. 13:1964;1267-1274.
15. Eckmann F., Schlag H. Kontrollierte doppelblind-studie zum wirksamkeitsnachweis von Tebonin forte bei patienten mit zerebrovaskulärer insuffizienz. Fortschr Med. 100:1982;1474-1478.
16. Gessner B., Voelp A., Klasser M. Study of the long-term action of Ginkgo biloba extract on vigilance and mental performance as determined by means of quantitative pharmaco-EEG and psychometric measurements. Arzneim-Forsch/Drug Res. 35:1985;1459-1465.
17. Halama P. Therapie mit Ginkgo biloba bei patienten cerebrovaskulärer insuffizienz und therapieresistenter depressiver symptomatik. Was leistet der spezialextrakt EGb 761? Ergebnisse einer palcebokontrolleirten doppelblinden pilotstudie. Therapiewoche. 40:1990;3760-3765.
18. Herrmann W.M., Kubicki S.K., Rohmel J. Vigilance classification system. development, sample values, and applications in nootropic drug research Zeitschr Gerontopsychol Psychiatr. 1:1988;1-33.
19. Hörr R. Expert report on clinical efficacy of EGb 761 for the central indications, Internal report. 1994;Dr. Willmar Schwabe GmbH & Co, Karlsruhe.
20. ® Clinical Documentation, 1992. IPSEN internal report, 12 August 1992.
21. Itil T.M., Erlap E., Tsambis E., Itil K.Z., Stein U. Central nervous system effects of Ginkgo biloba, a plant extract. Amer J Therapeut. 3:1996;63-73.
22. Itil T., Martorano D. Natural substances in psychiatry (Ginkgo biloba in dementia). Psychopharmacol Bull. 31:1995;147-158.
23. Künkel H. EEG profile of three different extractions of Ginkgo biloba. Neuropsychobiology. 27:1994;40-45.
24. Luthringer, R., d'Arbigny, P., Machler, J.P., 1995. Ginkgo biloba extract (EGb 761), EEG and event-related potentials mapping profile. In: Christen, Y., Courtois, Y., Droy-Lefaix, M.T. (Eds.), Advances in Ginkgo biloba extract research, Vol. 4. Effects of Ginkgo biloba extract (EGb 761) on aging and age-related disorders. Elsevier, Paris, pp. 107-118.
25. Luthringer R., d'Arbigny P., Minot R., Toussaint M., Dago K.T., Macher J.P. EEG and EPs mapping profile of Ginkgo biloba extract (EGb 761). Clin Neuropharm. 15(Suppl. 1):1992;152B.
26. Manocha A., Pillai K.K., Husain S.Z. Effect of Ginkgo biloba on chemoshock in mice. Indian J Pharmacol. 29:1997;198-200.
27. Maynert E.W., Van Dyke H.B. The metabolic fate of pentobarbital. J Pharmacol Exp Therapeut. 98:1950;174-179.
28. ®. Internal report. Dr. Willmar Schwabe GmbH & Co., Karlsruhe.
29. Nakanishi K., Habaguchi K. Biosynthesis of ginkgolide B, its diterpenoid nature, and origin of the tert-butyl group. J Am Chem Soc. 93:1971;3546-3547.
30. Pidoux B., Bastien C., Niddam S. Etude à double insu, face au placebo, des effets de l'extrait de Ginkgo biloba sur l'état clinique et l'EEG quantifié J Cerebr Blood Flow Metab. 3(Suppl 1):1983;5556-5557.
31. Pietri S., Maurelli E., Drieu K., Culcasi M. Cardioprotective and antioxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). J Mol Cell Cardiol. 29:1997;733-742.
32. Porsolt R.D., Martin P., Lenègre A., Fromage S., Drieu K. Effects of an extract of Ginkgo biloba (EGb 761) on "learned helplessness" and other models of stress in rodents. Pharmacol Biochem Behav. 36:1990;963-971.
33. Radzialowski F.M., Bousquet W.F. Circadian rhythm in hepatic drug metabolizing activity in the rat. Life Sci. 6:1967;2545-2548.
34. Rapin J.R., Lamproglou I., Drieu K., DeFeudis F.V. Demonstration of the "anti-stress" activity of an extract of Ginkgo biloba (EGb 761) using a discrimination learning task. Gen Pharmacol. 25:1994;1009-1016.
35. Schubert H., Halama P. Primary therapy-resistant depressive instability in elderly patients with cerebral disorders. efficacy of a combination of Ginkgo biloba extract EGb 761 with antidepressants Geriatr Forsch. 1:1993;45-53.
36. Sharma, H.S., Westman, J., Nyberg, F., Cervós-Navarro, J., Dey, P.K., 1994. Neuroprotective effects of EGb-761 in heat stress: experimental observations in the rat. In: (Abstr.) International Symposium on Pharmacology of Thermoregulation. Giessen, 7-14 August 1994.
37. Shifman, M.I., Fulop, Z.L., Hashemzadeh-Gargari, H., Stein, D.G., 1996. Effects of Ginkgo biloba extract (EGb 761) on behavioral recovery and expression of NGF, GAP-43 and β-actin mRNA after inducing unilateral entorhinal cortex lesions. In: Christen, Y., Droy-Lefaix, M.T., Macias-Nuǹez, J.F. (Eds.), Advances in Ginkgo biloba extract research, Vol. 5. Effects of Ginkgo biloba extract (EGb 761) on neuronal plasticity. Elsevier, Paris, pp. 61-74.
38. Simon P., Tillement J.-P., Lwoff J.-M., Boissier J.-R. Approche pharmacologique du mécanisme de la potentialisation des hypnotiques par certains inhibiteurs de la monoamine oxydase. Thérapie. 23:1968;849-861.
39. Simon P., Chermat R., Doaré L., Bourin M., Farinotti R. Interactions imprévues de divers psychotropes avec les effets du barbital et du pentobarbital chez la souris. J Pharmacol (Paris). 13:1982;241-252.
40. Sitzer G. Die zerebrovaskuläre insuffizienz. Der Kassenarzt. 17(18):1987;2-12. a.
41. ® forte bei patienten mit chronischer zerebrovaskulärer insuffizienz. Der Kassenarzt. 18:1987;28-35. b.
42. Spinnewyn B., Blavet N., Clostre F. Effet de l'extrait de Ginkgo biloba sur un modèle d'ischémie cérébrale chez la gerbille. Press Méd. 15:1986;1511-1515.
43. Vorberg G. GBE - Long term study concerning the major symptoms of age-related cerebral disorders. Clin Trials Journal. 22:1985;149-157.
44. Wada K., Sasaki K., Miura K., Yagi M., Kubota Y., Matsumoto T., Haga M. Isolation of bilobalide and ginkgolide A from Ginkgo biloba L. shorten the sleeping time induced in mice by anesthetics. Biol Pharm Bull. 16:1993;210-212.
45. Weinges K., Bähr W. Bilobalid A, ein neues sesquiterpen mit tert.-butyl-gruppe aus den Blättern von Ginkgo biloba L. Liebigs Ann Chem. 724:1969;214-216.
46. Yao Z., Boujrad N., Drieu K., Papadopoulos V. Anti-oxidant properties of ginkgolides. protection of testicular Leydig cell cytochrome P450scc activity and androgen formulation Packer L., Christen Y. Advances in Ginkgo biloba extract research, Vol. 7. Ginkgo biloba extract (EGb 761). lessons from cell biology:1998;129-138 Elsevier, Paris.